A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
复制标题
DOI：
10.18632/oncotarget.11726
复制
发表时间：
2016-10-25
期刊：
影响因子：
--
通讯作者：
Zhao J
中科院分区：
文献类型：
--
作者：
Wang W;Zhang L;Wang Z;Yang F;Wang H;Liang T;Wu F;Lan Q;Wang J;Zhao J
胶质母细胞瘤是恶性程度最高的肿瘤，死亡率高。MGMT的甲基化启动子导致这些患者对化疗的敏感性。然而，对于具有相似MGMT甲基化状态的胶质母细胞瘤患者，仍有其他因素影响预后。我们从中国脑胶质瘤基因组图谱(CGGA)和肿瘤基因组图谱(TCGA)的RNAseq数据中筛选出了三个基因。低风险组MGMT甲基化患者的生存期明显长于高风险组(中位生存期分别为1074d和372d，P=0.0033)。此外，在按甲基化和化疗分层的队列中，该标志的预后价值有显著差异(P=0.0473)，而在低危组和高危组以及未接受化疗的未甲基化的MGMT患者之间，其预后价值无显著差异。多因素分析显示，危险评分是独立的预后因素(P=0.004)。总之，我们的结果表明，基于生物信息学分析，该信号对MGMT启动子甲基化的胶质母细胞瘤患者具有预后价值。
Glioblastoma is the most malignant tumor and has high mortality rate. The methylated prompter of MGMT results in chemotherapy sensitivity for these patients. However, there are still other factors that affected the prognosis for the glioblastoma patients with similar MGMT methylation status. We developed a signature with three genes screened from the whole genome mRNA expression profile from Chinese Glioma Genome Atlas (CGGA) and RNAseq data from The Cancer Genome Atlas (TCGA). Patients with MGMT methylation in low risk group had longer survival than those in high risk group (median overall survival 1074 vs. 372 days; P = 0.0033). Moreover, the prognostic value of the signature was significant difference in cohorts stratified by MGMT methylation and chemotherapy (P=0.0473), while there is no significant difference between low and high risk group or unmethylated MGMT patients without chemotherapy. Multivariate analysis indicated that the risk score was an independent prognosis factor (P = 0.004). In conclusion, our results showed that the signature has prognostic value for patients with MGMT promoter-methylated glioblastomas based on bioinformatics analysis.